Tear Trough Filler in Korea (2026): Candidacy, Risks and Realistic Results

Sep 1

5 min read

Tear trough filler is a hyaluronic acid injection placed in the hollow between the lower eyelid and the cheek to reduce the shadow that reads as under-eye darkness or tiredness. In Korea it is typically performed with a blunt cannula, deep to the orbicularis muscle, using small volumes.

It is also one of the most over-recommended injectable procedures worldwide, and one of the least suitable for a substantial share of the people who ask for it. Most guides describe the technique and the price. This one covers the candidacy screen first, because the single biggest determinant of a good tear trough outcome is not the injector's skill or the product — it is whether the hollow is actually the cause of what you are seeing in the mirror.

What Actually Causes Under-Eye Darkness

Under-eye shadowing has at least four distinct mechanisms, and filler addresses only one of them well.

True volume loss — a real concavity at the orbital rim casting a shadow. This is the filler-responsive group.
Pigmentation — melanin deposition in the periorbital skin, common in Fitzpatrick III to V skin. Filler does nothing for this and can make it look worse by lifting pigmented skin forward.
Vascular visibility — thin skin over the underlying vasculature producing a blue-grey tint. Filler may help marginally by adding depth, but often disappoints.
Pseudoherniated orbital fat — bulging fat pads creating a bulge above the hollow. Filling below a bulge can accentuate the step rather than smooth it; this group is often better served surgically.

A competent consultation should distinguish these explicitly, ideally with a simple stretch test and side lighting. If a clinic proposes filler without examining which mechanism dominates in your face, that is the moment to slow down.

Who Is Not a Good Candidate

The honest exclusion list is longer than marketing suggests. Poor candidates commonly include people with significant fat pad herniation, marked lower lid laxity, a history of fluid retention or morning puffiness, very thin skin with prominent vasculature, active periorbital dermatitis, and those whose darkness is predominantly pigmentary.

There is also a body of clinical observation that patients with a strong negative vector — where the cheek sits behind the plane of the eye — tolerate tear trough filler poorly and are more prone to persistent puffiness. In these cases mid-cheek support, energy-based skin tightening, or surgical lower blepharoplasty may address the underlying problem more durably than filling the trough itself.

Why This Area Carries Higher Risk Than Other Filler Sites

The periorbital region is anatomically unforgiving. The skin is among the thinnest on the body, the space is small, lymphatic drainage is limited, and the area contains vessels with connections to the ophthalmic circulation.

The rare but serious complication is vascular occlusion, which in periorbital injections carries a risk of visual compromise. Published case reports of filler-associated visual loss disproportionately involve the glabella, nose, and periorbital region. This risk is low in absolute terms and is reduced — not eliminated — by cannula technique, aspiration where appropriate, low injection pressure, and small aliquots. The practical implication for patients: this is not a procedure to select on price or convenience, and the injector should be a physician with documented experience in this specific area and immediate access to hyaluronidase.

The Complication Nobody Warns You About: Persistent Puffiness

Here is the gap in most competing content. The complication patients actually encounter is rarely dramatic — it is chronic malar oedema, a soft persistent puffiness under the eye that appears weeks to months after treatment and can last as long as the filler remains.

The mechanism relates to hyaluronic acid's water-binding capacity combined with the region's limited lymphatic drainage. It is more common with hydrophilic products, with over-correction, and with placement that is too superficial. It is treatable — hyaluronidase dissolves the product — but that means an additional procedure, an additional cost, and for a medical tourist, a problem that surfaces after you have flown home. Ask explicitly, before treatment, what the clinic's protocol and cost structure is for hyaluronidase correction if you are no longer in Korea.

Product Choice and Volume

The tear trough is a low-volume, low-hydrophilicity area. Products chosen for this region are typically among the softer, less hydrophilic hyaluronic acid formulations, and total volume is usually small — often in the range of 0.5 to 1.0 mL across both sides, sometimes less.

Under-correction is the accepted convention. A conservative first session with review at two to four weeks, then a top-up if genuinely needed, produces better outcomes than a single generous session. Be cautious of any offer framed around a full syringe per side as a package deal; volume packaging is a commercial construct, not a clinical one. Sequencing also matters — cheek support is often established before the trough is addressed, because supporting the mid-face sometimes reduces the trough enough that little or no direct filling is needed.

Timeline, Longevity, and What to Expect

Expect bruising as a realistic possibility rather than an unlucky outcome — the periorbital region bruises readily. Swelling in the first 48 to 72 hours is common and can temporarily look worse than the starting point. Most clinics advise assessing the result at two to four weeks.

Longevity in this area is often reported as longer than in mobile regions such as the lips, with many patients seeing persistence beyond 12 months, and some considerably longer. Longer duration cuts both ways: a good result lasts, but so does an over-filled one. For international patients this argues for building in a review appointment before departure and for confirming, in writing, what follow-up support is available remotely.

Alternatives Worth Considering First

Depending on the dominant mechanism, several alternatives may address the concern more appropriately. Pigment-driven darkness responds better to topical and laser-based approaches than to volume. Skin quality and fine crepiness may respond to energy-based devices or biostimulatory injectables. True fat pad herniation with skin excess is a surgical question. And a meaningful share of under-eye appearance is driven by sleep, allergy, and fluid status — unglamorous variables, but ones worth excluding before injecting anything into the orbital region. Our overview of botox versus filler as an anti-aging decision framework sets out how these categories divide.

Frequently Asked Questions

Does tear trough filler hurt?

Most clinics use topical anaesthetic and many products contain lidocaine. Cannula technique typically involves one entry point per side. Patients commonly describe pressure rather than sharp pain, though individual experience varies.

How long does it last?

Frequently longer than filler in mobile areas — often beyond 12 months, sometimes considerably longer. Duration varies with product, placement depth, volume, and individual metabolism.

Can it be reversed?

Hyaluronic acid fillers can be dissolved with hyaluronidase. This is a genuine advantage of HA products in this region and a reason to be cautious about permanent or semi-permanent alternatives near the eye.

Will it fix dark circles?

Only if the darkness is caused by a shadow from volume loss. Pigmentary and vascular darkness generally do not respond well, and filling can occasionally make pigmented skin more noticeable.

Is fat grafting better than filler here?

Fat grafting offers potential permanence but is less predictable in the periorbital region, where irregularity and lumpiness are harder to correct and cannot be dissolved. Many clinicians treat filler as the reversible first step and reserve grafting for selected cases.

How to Decide

Confirm the mechanism before choosing the treatment. If a clinic cannot explain which of the four causes dominates in your face, you do not yet have enough information to consent. Then prioritise injector qualification and hyaluronidase availability over price, start under-corrected, and plan a review before you fly home.

This article is general information for international patients and is not medical advice. Individual outcomes and risks vary. Consult a licensed physician who has examined you in person.

Sources

Background and safety context drawn from: Korea Health Industry Development Institute (KHIDI) · Ministry of Food and Drug Safety (MFDS), Korea · PubMed — tear trough filler complications literature.